2003
The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer
Herbst RS, O’Reilly M. The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Seminars In Oncology 2003, 30: 113-123. PMID: 12908142, DOI: 10.1016/s0093-7754(03)00269-0.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerAnti-epidermal growth factor receptor agentsNovel biologic therapiesEarly clinical investigationConventional cytotoxic agentsNovel combination therapiesTreatment of malignanciesAnti-angiogenic agentsPresent preclinical dataBiologic therapyOngoing trialsCombination therapyPreclinical dataReceptor agentsToxicity profileClinical investigationClinical developmentConventional modalitiesCytotoxic agentsRadiotherapyTherapyCancerHuman cancers
2001
Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin
Herbst R, Lee A, Tran H, Abbruzzese J. Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin. Current Oncology Reports 2001, 3: 131-140. PMID: 11177745, DOI: 10.1007/s11912-001-0013-8.Peer-Reviewed Original ResearchConceptsPhase I trialI trialClinical studiesHuman endostatinTumor vasculatureSolid tumor malignanciesAnti-angiogenic agentsAnti-angiogenic mechanismAnti-angiogenic compoundsToxic cancer treatmentsAdvanced diseaseBlood vessel supplyCenter trialMinimal diseaseTumor sizeNovel agentsSurrogate endpointsNew agentsSide effectsBiologic mechanismsSingle agentAngiogenesis inhibitorsGrowth-inhibiting moleculesNon-toxic agentsTumor growth